(2022). Correction Notice: Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies. Wiley.
Chicago Style (17th ed.) CitationCorrection Notice: Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but Not in Myeloid Malignancies. Wiley, 2022.
MLA (9th ed.) CitationCorrection Notice: Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but Not in Myeloid Malignancies. Wiley, 2022.
Warning: These citations may not always be 100% accurate.